<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03010124</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A01183-46</org_study_id>
    <secondary_id>2015/2290</secondary_id>
    <nct_id>NCT03010124</nct_id>
  </id_info>
  <brief_title>Prognostic and Predictive Biomarkers in Ovarian Cancers</brief_title>
  <acronym>OvBIOMark</acronym>
  <official_title>Prognostic and Predictive Biomarkers in Ovarian Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators therefore propose to conduct a biological study of prospectively collected
      patient tumour samples, ascites, blood and other residual samples (feces, urine, cervical
      smear) throughout the disease course where markers (at diagnosis and their change with
      treatment) will be correlated to outcome in order to investigate how genetic diversity in OC
      prior to treatment and adaptation following treatment contribute to chemotherapy resistance.
      In addition freshly collected ascitic samples (and tumour samples) will be subjected to ex
      vivo DNA repair functional assays and isolated in primary culture (and established as
      xenografts) for target validation experiments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Correlation of baseline biomarkers with PFS will occur at 12 months following last patient inclusion</time_frame>
    <description>up to 12 months</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with ovarian cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>Patients with ovarian cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. New patient with a diagnosis of OC, or

          2. Previously treated patient with frozen or formalin fixed paraffin embedded primary
             tumour sample available that can be retrieved by the center presenting with
             progressive disease, and consenting to CT guided biopsy of relapsed disease, or

          3. Previously treated patient with frozen or formalin fixed paraffin embedded primary
             tumour sample available that can be retrieved by the center scheduled for surgery for
             relapsed disease.

          4. Signed informed consent

          5. Age â‰¥ 18

          6. Patient affiliated to a social security regimen or beneficiary of the same

        Exclusion Criteria:

          1. Patients who do not fit the inclusion criteria and those who refuse an antitumoral
             treatment;

          2. Coagulation abnormalities that contra-indicates the biopsy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandra LEARY, MD</last_name>
    <phone>0142114389</phone>
    <phone_ext>+33</phone_ext>
    <email>alexandra.leary@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ariane DUNANT</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>ariane.dunant@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra LEARY, MD</last_name>
      <phone>0142114389</phone>
      <phone_ext>+33</phone_ext>
      <email>alexandra.leary@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ariane DUNANT</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>ariane.dunant@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2017</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

